ArticleVaccines2022
Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.Current topics in medicinal chemistry · 2025Review
- Sequential Immunization with Vaccines Based on SARS-CoV-2 Virus-like Particles Induces Broadly Neutralizing Antibodies.Vaccines · 2024Article
- Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population.Molecules (Basel, Switzerland) · 2023Review
- Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: AnAntibodies (Basel, Switzerland) · 2023Article
- Review
- Review
- Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants.Vaccines · 2023Review
- Review
- Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.Frontiers in immunology · 2023Review
- Tomato flu outbreak in India.The Lancet. Respiratory medicine · 2023Article
- Review
- An Impact of COVID-19 on Cancer Care: An Update.Vaccines · 2022Review
- Recent review of COVID-19 management: diagnosis, treatment and vaccination.Pharmacological reports : PR · 2022Review
- Assessment of the COVID-19 vaccine market landscape in 2021 relative to challenges in low- and middle-income countries.Human vaccines & immunotherapeutics · 2022Article
- Review
- Co-infection associated with SARS-CoV-2 and their management.Future science OA · 2022Review
- Pseudoscience and fraudulent products for COVID-19 management.Environmental science and pollution research international · 2022Review
- Therapeutics to tackle Omicron outbreak.Immunotherapy · 2022Article
- SARS-CoV-2 variants and vulnerability at the global level.Journal of medical virology · 2022Review
- Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.Viruses · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Omicron variant of SARS-CoV-2 is emerging in communities where people were previously infected with SARS-CoV-2 and are now being vaccinated, or where many people have received two or three coronavirus vaccination doses. More than 130 countries around the globe have implemented booster dose programs for tackling omicron endemics. Despite early findings shows that booster doses may improve omicron protection, more research is needed to establish vaccination efficacy. This short communication tries to critically discuss the research work findings around booster dose strategy for omicron endemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.